- All sections
- C - Chemistry; metallurgy
- C07D - Heterocyclic compounds
- C07D 261/18 - Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen
Patent holdings for IPC class C07D 261/18
Total number of patents in this class: 312
10-year publication summary
|
23
|
26
|
36
|
33
|
20
|
28
|
28
|
20
|
10
|
4
|
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Theravance Biopharma R&D IP, LLC | 550 |
47 |
| Proteostasis Therapeutics, Inc. | 72 |
9 |
| F. Hoffmann-La Roche AG | 7958 |
8 |
| Bristol-myers Squibb Company | 5080 |
6 |
| Boehringer Ingelheim International GmbH | 4629 |
6 |
| Denali Therapeutics Inc. | 203 |
6 |
| The Provost, Fellows, Foundation Scholars, and The Other Members of Board, of The College of The Holy and Undivided Trinity of Queen Elizabeth, Near Dublin | 157 |
6 |
| Shionogi & Co., Ltd. | 914 |
6 |
| The University of Queensland | 666 |
6 |
| VALO Health, Inc. | 147 |
6 |
| Hoffmann-La Roche Inc. | 3060 |
5 |
| Sumitomo Chemical Company, Limited | 8808 |
5 |
| The Board of Trustees of the University of Illinois | 2623 |
5 |
| Astellas Pharma Inc. | 1145 |
5 |
| Bayer Cropscience AG | 2241 |
4 |
| Board of Regents, The University of Texas System | 5370 |
4 |
| Mitsui Chemicals, Inc. | 3134 |
4 |
| Cornell University | 3036 |
4 |
| Epizyme, Inc. | 383 |
4 |
| Theravance, Inc. | 93 |
4 |
| Other owners | 162 |